New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:55 EDTINFI, INFI, SFE, SFE, CELG, CELG, IMGN, IMGN, NVS, NVS, QSII, QSII, THOR, THORJPMorgan to host a conference
31st Annual Global Healthcare Conference is being held in San Francisco on January 7-10 with webcasted company presentations to begin on January 7 at 10 am; not all company presentations may be webcasted. Webcast Link
News For INFI;SFE;CELG;IMGN;NVS;QSII;THOR From The Last 14 Days
Check below for free stories on INFI;SFE;CELG;IMGN;NVS;QSII;THOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 29, 2014
10:04 EDTNVSNovartis hematopoietic support for ALL patients granted orphan status
Novartis' hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor antagonist was granted orphan designation as a hematopoietic support in patients with acute lymphoblastic leukemia, or ALL, the FDA stated. Reference Link
08:46 EDTNVSNovartis has a conference call hosted by JPMorgan
JPMorgan Analyst Vosser hosts a conference call with CEO Joe Jimenez on September 5 at 8 am.
August 28, 2014
08:40 EDTNVSPositive data on Novartis LCZ696 could raise sales outlook, says Leerink
Subscribe for More Information
August 26, 2014
11:20 EDTCELGCelgene added to short term buy list at Deutsche Bank
Subscribe for More Information
09:35 EDTCELGActive equity options trading on open
Subscribe for More Information
07:29 EDTSFEThree Part Advisors to hold a conference
Midwest IDEAS Conference to be held in Chicago on August 26-27.
05:49 EDTQSIINextGen Healthcare partners with North Carolina Pediatric Associates
Subscribe for More Information
August 25, 2014
12:19 EDTCELGOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTCELGBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
10:00 EDTTHOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:05 EDTTHORThoratec downgraded at Piper Jaffray
Subscribe for More Information
06:17 EDTTHORThoratec downgraded to Neutral from Overweight at Piper Jaffray
August 20, 2014
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
11:09 EDTINFIHigh option volume stocks
Subscribe for More Information
08:02 EDTCELGBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
09:38 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use